2011
A clinically relevant gene signature in triple negative and basal-like breast cancer
Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L, Gaetje R, Solbach C, Ahr A, Metzler D, Schmidt M, Müller V, Holtrich U, Kaufmann M. A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Research 2011, 13: r97. PMID: 21978456, PMCID: PMC3262210, DOI: 10.1186/bcr3035.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerBasal-like triple-negative breast cancerBreast cancerPrognostic markerMolecular subtypesMultivariate analysisBasal-like molecular subtypeClaudin-low molecular subtypeBasal-like breast cancerAttractive novel therapeutic targetB cell presenceHigh expressionER-positive cancersHigh histological gradeHigher B cellsIL-8 pathwayIL-8 activityNegative breast cancerNew prognostic markerNovel therapeutic targetBiology-based therapiesNon-neoplastic cell populationsRelevant gene signaturesRoutine clinicopathological variablesResultsSeventy-three percent
2009
Triple-negative breast cancer—current status and future directions
Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer—current status and future directions. Annals Of Oncology 2009, 20: 1913-1927. PMID: 19901010, DOI: 10.1093/annonc/mdp492.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerBasal-like breast cancerBreast cancerBreast cancer—current statusStandard cytotoxic chemotherapy regimensHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Common cytotoxic agentsCytotoxic chemotherapy regimensGrowth factor receptor 2Factor receptor 2Chemotherapy regimensClinical featuresUnfavorable prognosisProgesterone receptorLack of expressionNovel agentsReceptor 2Cytotoxic agentsPrognosisComplete concordanceCancerGene expression analysisHigh-throughput gene expression analysisRegimens